Takeshi Ito - Santen Pharmaceutical Director

SNPHY Stock  USD 9.75  0.07  0.72%   

Director

Mr. Takeshi Ito was serving as Senior Managing Executive Officer, Director of Ophthalmology Business and Director in Santen Pharmaceutical Co., Ltd. effective April 1, 2019. He joined the Company in April 1982. His previous titles include Executive Officer, Managing Executive Officer, Manager of Business Development Office in Main Business Development Unit, Manager of Planning Office in Research Development Strategy Supervisor Unit, Director of Surgical Business, Senior Director of Research Development in Main Research Development Unit and Senior Director of Pharmaceutical Sales in Pharmaceutical Business Unit in the Company. since 2019.
Age 64
Tenure 5 years
Phone81 6 7664 8621
Webhttps://www.santen.com

Santen Pharmaceutical Management Efficiency

Santen Pharmaceutical's management efficiency ratios could be used to measure how well Santen Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 32.93 B in total debt with debt to equity ratio (D/E) of 0.1, which may suggest the company is not taking enough advantage from borrowing. Santen Pharmaceutical has a current ratio of 2.43, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Santen Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Santen Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Santen Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Santen to invest in growth at high rates of return. When we think about Santen Pharmaceutical's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Julie BrownRoche Holding
56
Carolyn BertozziEli Lilly And
53
Dimitri AzarNovartis AG ADR
59
Rochelle LazarusMerck Company
71
Carlos RepresasMerck Company
72
Andreas PlantaNovartis AG ADR
65
Ton BuechnerNovartis AG ADR
55
Pierre LandoltNovartis AG ADR
70
Thomas GlocerMerck Company
61
Mary CoeMerck Company
54
Marillyn HewsonJohnson Johnson
67
Gabrielle SulzbergerEli Lilly And
60
Deborah DiSanzoAstraZeneca PLC ADR
59
William KaelinEli Lilly And
63
Ellen MarramEli Lilly And
71
Marschall RungeEli Lilly And
66
Mark WeinbergerJohnson Johnson
59
Pius BascheraRoche Holding
65
Christoph FranzRoche Holding
58
Peter WendellMerck Company
70
Patricia RussoMerck Company
68
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan. Santen Pharmaceutical operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 4315 people. Santen Pharmaceutical Co [SNPHY] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Santen Pharmaceutical Leadership Team

Elected by the shareholders, the Santen Pharmaceutical's board of directors comprises two types of representatives: Santen Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Santen. The board's role is to monitor Santen Pharmaceutical's management team and ensure that shareholders' interests are well served. Santen Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Santen Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Satoshi Suzuki, Executive Officer, Chief Director of Planning
Kanoko Ohishi, Independent Director
Nikolas Tripodis, Chief Officer
Noriaki Yamamoto, CIO, Head of Information Systems Division and Corporate Officer
Akira Kurokawa, CEO and President Director, Member of Nominating Committee, Member of Executive Compensation Committee and Member of Corporate Strategy Committee
Hidetaka Mizutani, Manager of Finance & Accounting Group
Kenji Morishima, Executive Officer, Chief Director of Human Resources & Organization Development and CSR
Nobuko Kato, Chief Officer
Sadatoshi Furukado, Senior Managing Executive Officer, Director of Medical Business, Director
Ken Araki, Executive Officer, Senior Director of Global Business Development
Mika Masunari, G Officer
Masamichi Sato, Head of CSR and General Affairs Division and Sr. Corporate Officer of Corporate Devel.
Kazuo Koshiji, CFO, Head of Fin. Division and Sr. Corporate Officer
Kaori Itagaki, Gen Group
Akihiro Tsujimura, Executive Officer, Director of Asia Business
Takeshi Ito, Executive Officer, Senior Director of Medicine Sales in Medicine Business Unit
Shinichi Teramachi, Head Officer
Frank Binder, Executive Officer, Chief Director of Supply Chain
Ippei Kurihara, Japan Department
Yutaro Shintaku, Independent Director
Akihiro Okumura, Independent Director
Yutaro Shinta, Independent Director
Jyrki Liljeroos, Executive Officer and Presidentident of Subsidiary
Shiro Hatagami, Manager of Finance & Accounting Group
Keizo Nakada, Executive Officer, Chief Director of Product Supply
Ko Takahashi, Executive Officer
Akio Kimura, Executive Officer, Chief Director of Reliability Guarantee
Miki Fujima, Executive Officer, Chief Director of Human Resources
Naveed Shams, Chief Scientific Officer, Executive Officer and Presidentident and CEO of Subsidiary
Atsutoshi Ohta, Executive Officer, Chief Director of Production & Logistics
Hiroyuki Yamazaki, Executive Officer, Senior Director of Pharmaceutical Sales in Pharmaceutical Business Unit
Takahiro Morita, Executive Officer, Senior Director of Pharmaceutical Sales in Pharmaceutical Business Unit
Ye Liu, Executive Officer, General Manager of Subsidiary
Takayuki Katayama, Independent Director
Luis Iglesias, Executive Officer
Shigeo Taniuchi, Executive Officer and Presidentident of Subsidiary
Kunihito Minakawa, Independent Director
Minori Hara, Chief Officer

Santen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Santen Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Santen Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Santen Pharmaceutical's short interest history, or implied volatility extrapolated from Santen Pharmaceutical options trading.

Currently Active Assets on Macroaxis

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Santen Pharmaceutical Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.
Note that the Santen Pharmaceutical information on this page should be used as a complementary analysis to other Santen Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Complementary Tools for Santen Pink Sheet analysis

When running Santen Pharmaceutical's price analysis, check to measure Santen Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santen Pharmaceutical is operating at the current time. Most of Santen Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Santen Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santen Pharmaceutical's price. Additionally, you may evaluate how the addition of Santen Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Equity Valuation
Check real value of public entities based on technical and fundamental data
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Please note, there is a significant difference between Santen Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Santen Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Santen Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.